Please Refer the Following Patients to the Division of Hepatogastroenterology
-
Acute hepatitis
-
HBeAg-positive chronic hepatitis B
-
HBeAg-negative chronic hepatitis B with ALT (GPT) level over 2 times the upper normal limit
-
Chronic hepatitis C with ALT (GPT) level over the upper normal limit
-
Chronic hepatitis of various and unknown etiologies
-
Liver cirrhosis
-
Hepatocellular carcinoma
To enhance health care and treatment of patients with chronic hepatitis, the Bureau of National Health Insurance (BNHI) launched the reimbursement program for the treatment of chronic hepatitis B and C on October 1st, 2003 and further updated it to include the following categories of patients in December 2005, November 2006, July 2008, November 2009, July 2010, June 2011, February 2013, and December 2015:
Chronic Hepatitis B
-
HBsAg-positive patients with clinical decompensation (jaundiced or prolonged prothrombin time over 3 seconds)
-
HBsAg-positive patients undergoing organ transplant or cancer chemotherapy develops HBV reactivation
-
HBsAg-positive over 6 months, HBeAg-positive over 3 months, and ALT (GPT) level over 5 times the upper normal limit
-
HBsAg-positive over 6 months, HBeAg-positive over 3 months, ALT (GPT) level between 2-5 times the upper normal limit, and HBcAg-positive by immunohistochemical staining of the liver biopsy tissue or HBV DNA over 2000 IU/mL.
-
HBsAg-positive over 6 months, HBeAg-negative over 3 months, ALT (GPT) level over 2 times the upper normal limit (twice with 3 months apart) and HBcAg-positive by immunohistochemical staining of the liver biopsy tissue or HBV DNA over 2000 IU/mL.
-
Adefovir, Tenofovir and Entecavir 1 mg for those patients who develop Lamivudine, Entecavir 0.5 mg, Telbivudine, Tenofovir virologic breakthrough or secondary treatment failure on antiviral therapy defined as a confirmed increase in HBV DNA level of greater than 1 log10 IU/mL from nadir.
Chronic Hepatitis C
-
Anti-HCV positive
-
ALT (GPT) level over the upper normal limit
-
Liver fibrosis stage ≧1 by biopsy or HCV RNA (+)
-
Compensated liver function
For those patients fulfilling the above criteria for reimbursement, please phone us at (04) 2205-2121 EXT 2264 for further information and appointment with our physicians.
Hepatitis is treatable and can lead to liver cirrhosis and hepatocellular carcinoma if left untreated. We encourage you to undergo regular surveillance to detect early stage disease for early treatment.
-
Initial evaluation by physicians
-
Patient referral to Liver Unit forcounseling
-
Determine treatment strategy
-
Patient enrollment and registration
-
Initiate antiviral therapy
-
Assess side effects and therapeutic responses regularly
中國醫藥大學附設醫院
連絡電話：(04)22052121分機 3207
若有任何疑問，請不吝與我們聯絡
Back
